News Headlines

  1. Italfarmaco And JCR Pharmaceuticals Enter Into Exclusive License Agreement For The Development And Potential Commercialization Of Novel Investigational Therapy For Hunter Syndrome In The United States, Europe, And Latin America 10/2/2026

    Italfarmaco S.p.A. (“Italfarmaco”) and JCR Pharmaceuticals Co., Ltd. today announced an exclusive license agreement to develop and commercialize JR-141 in the United States, Europe, and Latin America (“licensed territories”) upon regulatory approval.

  2. Samsung Bioepis And Teva Expand Strategic Partnership To Advance Up To Six Potential Biosimilar Candidates 10/1/2026

    Samsung Bioepis Co., Ltd. and Teva Pharmaceutical Industries Ltd. today announced that the companies have entered into a global license, development, and commercialization agreement for up to six potential biosimilar candidates, with two confirmed investigational biosimilar candidates, SB41, a biosimilar candidate referencing Fasenra1 (benralizumab), and SB44, a biosimilar candidate referencing Ilaris2 (canakinumab).

  3. MedPharm Inks Deal To Support Global Pharmaceutical Company With Commercial Site Transfer 10/1/2026

    MedPharm, a global leader in topical and transdermal contract drug development and manufacturing, today announced that it has signed a new agreement with a global pharmaceutical company to support the commercial site transfer and commercial manufacturing of their branded specialty topical pharmaceutical product.

  4. Synthego And Biomay Collaborate To Accelerate Access To Mrna Manufacturing And CRISPR Solutions 10/1/2026

    Biomay, a contract development and manufacturing organization (CDMO) specializing in mRNA manufacturing, lipid nanoparticle (LNP) formulation, aseptic fill-finish, plasmid DNA, and recombinant proteins, and Synthego, a leading provider of CRISPR solutions, today announced a non-exclusive collaboration to market, promote, and resell Biomay products and services to Synthego customers and end users in North America.

  5. Piramal Pharma Solutions And NP2 To Complete Cyclophosphamide Development Phase Next Month 9/30/2026

    Piramal Pharma Solutions ("PPS"), a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. ("PPL") (NSE: PPLPHARMA) (BSE: 543635), and its partner NP2, a nonprofit generic drug manufacturer, today announced their plans to finish the drug development phase of the generic cancer drug cyclophosphamide in October.

  6. OnDosis And Adare Pharma Solutions Announce Strategic Collaboration To Advance OnDosis's Lead U.S. ADHD Program 9/30/2026

    OnDosis AB (“OnDosis”), a Swedish life science company developing drug device combinations for precision dosing of oral solid medicines based on the Dosage Manager device platform, and Adare Pharma Solutions (“Adare”), a technology-driven, integrated contract development and manufacturing organization (CDMO), today announced a strategic collaboration.

  7. Serán Bioscience Strengthens Spray Dry Capabilities With Growth Investment From Biospring Partners To Accelerate Commercial Expansion And Meet Surging Customer Demand 9/30/2026

    Serán Bioscience (“Serán” or “the Company”), a leading contract development and manufacturing organization (CDMO) specializing in development, analytical and manufacturing solutions to pharmaceutical and biotechnology companies, today announced a growth investment led by Biospring Partners with continued participation from existing investors Vivo Capital, Bain Capital Life Sciences (“Bain Capital”), as well as Serán’s executive leadership.

  8. ALK Expands Strategic Tablet Supply Partnership With Catalent 9/30/2026

    ALK today announced that it has expanded its long-standing contract manufacturing partnership with Catalent, Inc. ("Catalent"), a leader in enabling the development and supply of better treatments for patients worldwide.

  9. Genezen Partners With Nevena Lešević And University Of Missouri To Advance Personalized AAV9 Gene Therapy For Her Son With Ultra-Rare ARCA2 9/29/2026

    Genezen, a gene therapy contract development and manufacturing organization (CDMO), today announced a partnership with Nevena Lešević of Lazarevac, Serbia to support the manufacturing of an AAV serotype 9 gene therapy for an N-of-1 clinical trial to address her son Kosta’s autosomal recessive spinocerebellar ataxia-2 (ARCA2) disorder caused by a PMPCA gene mutation.

  10. Hengrui Pharma And Novo Enter Exclusive License Agreement For Once-Weekly Oral GLP-1/GIP Dual Receptor Agonist HRS-1596 9/29/2026

    Hengrui Pharma (600276.SH; 01276.HK) today announced that it has entered into a license agreement with Novo Nordisk (Novo) for HRS-1596, a phase I-ready glucagon-like peptide-1 receptor (GLP-1R) and gastric inhibitory polypeptide receptor (GIPR) dual agonist, with potential for once-weekly oral dosing.